FOXO4-DRI: Molecular Structure

Molecular Structure and Properties#

FOXO4-DRI is a synthetic peptide with a molecular weight of approximately 4826.5 Da, designed using the D-Retro-Inverso (DRI) strategy to target the FOXO4-p53 protein-protein interaction within senescent cells. Unlike conventional peptides built from naturally occurring L-amino acids, FOXO4-DRI is composed entirely of D-amino acids arranged in a reversed sequence order. This dual modification -- chirality inversion combined with sequence reversal -- represents a specialized approach in peptide medicinal chemistry aimed at preserving biological activity while dramatically enhancing metabolic stability.

The peptide was first described by Baar, Brandt, Putavet et al. in their 2017 publication in the journal Cell, where it was developed at the Erasmus University Medical Center in Rotterdam, Netherlands, under the direction of Peter de Keizer.

The D-Retro-Inverso Design Principle#

What Are D-Amino Acids?#

Amino acids exist in two mirror-image forms: L-amino acids and D-amino acids. All naturally occurring proteins in mammals are composed of L-amino acids. Cellular proteases -- the enzymes responsible for degrading peptides and proteins -- have evolved to recognize and cleave peptide bonds formed between L-amino acids. D-amino acids are the mirror-image enantiomers of their L-counterparts. Because proteases are stereospecific, they generally cannot recognize or cleave peptide bonds formed between D-amino acids. This chirality difference is the foundation of the protease resistance that D-amino acid peptides exhibit.

The Retro-Inverso Concept#

Simply replacing all L-amino acids with D-amino acids in a peptide (an "all-D" peptide) would reverse the direction of the peptide backbone's amide bonds relative to the side chains. This reversal would alter the spatial positioning of the amino acid side chains, which are the primary mediators of protein-protein binding interactions. The side chain topology of a simple all-D peptide would not match the original L-peptide's binding surface.

The retro-inverso approach solves this problem by simultaneously reversing the sequence order. When both modifications are applied together -- D-amino acids and reversed sequence -- the resulting peptide presents its side chains in a topological arrangement that approximates the original L-peptide's binding surface. The backbone directionality is reversed by using D-amino acids, and the sequence reversal compensates for this, placing side chains in positions that mimic the native interaction interface.

This principle can be summarized as follows:

Limitations of the DRI Approach#

The structural mimicry achieved by the DRI strategy is not perfect. The peptide backbone of a DRI peptide differs from the native L-peptide in hydrogen bonding patterns, as amide NH and carbonyl groups are interchanged relative to the L-peptide backbone. For interactions that depend heavily on backbone-mediated contacts (such as hydrogen bonds between backbone atoms and the target protein), the DRI peptide may not fully replicate the native binding. However, for interactions dominated by side chain contacts -- as is typical for many protein-protein interaction interfaces -- the DRI approach can provide effective mimicry.

In the case of FOXO4-DRI, the peptide targets the FOXO4-p53 binding interface, a protein-protein interaction surface. Such interfaces are generally mediated by side chain contacts across a relatively flat binding surface, making this a suitable target for the DRI strategy.

Origin of the FOXO4-DRI Sequence#

The sequence of FOXO4-DRI is derived from the region of the FOXO4 (Forkhead box O4) transcription factor that directly mediates binding to the tumor suppressor protein p53. In senescent cells, FOXO4 becomes upregulated and forms a complex with p53 within promyelocytic leukemia (PML) nuclear bodies. This interaction sequesters p53 away from its pro-apoptotic transcriptional targets, effectively protecting the senescent cell from undergoing apoptosis.

Baar et al. identified the minimal FOXO4 domain responsible for p53 binding and synthesized a peptide corresponding to this region. The native L-amino acid version of this peptide was able to disrupt the FOXO4-p53 interaction in cell-based assays. However, the L-peptide was rapidly degraded by cellular proteases, limiting its effective duration of action and its utility for in vivo applications.

To overcome this limitation, the researchers applied the DRI strategy: they reversed the sequence and synthesized it using D-amino acids, producing FOXO4-DRI. The resulting peptide retained the ability to competitively disrupt the FOXO4-p53 interaction while being substantially resistant to enzymatic degradation.

Comparison with the L-Peptide Version#

The L-amino acid version of the FOXO4-p53 interfering peptide served as a critical control in the Baar et al. study. Both the L-peptide and the DRI peptide demonstrated the ability to disrupt FOXO4-p53 binding and induce apoptosis in senescent cells in vitro. However, the DRI version showed markedly superior performance in vivo, attributed to its protease resistance and correspondingly extended effective half-life in biological systems.

The exact plasma half-life of FOXO4-DRI has not been quantitatively determined in published pharmacokinetic studies. The assertion of an extended half-life relative to the L-peptide is inferred from the general principle that D-amino acid peptides resist mammalian protease degradation and from the observed in vivo efficacy following systemic administration in mice.

Chemical and Physical Properties#

FOXO4-DRI has a molecular weight of approximately 4826.5 Da, placing it in the intermediate range for therapeutic peptides. At this size, the peptide is too large for oral absorption and requires parenteral administration (injection). The exact molecular formula and CAS number have not been established in the publicly available literature.

The peptide's D-amino acid composition confers several distinctive physicochemical properties:

• Protease resistance: The primary advantage of the D-amino acid construction. Standard mammalian proteases, including trypsin, chymotrypsin, and serum peptidases, show minimal activity against D-amino acid peptide bonds.
• Reduced immunogenicity potential: D-amino acid peptides are generally considered less immunogenic than their L-counterparts, as MHC class I and II molecules have evolved to present L-amino acid peptide fragments for T cell recognition. However, this has not been systematically evaluated for FOXO4-DRI.
• Cell penetration: FOXO4-DRI must cross the cell membrane to reach its intracellular targets (FOXO4-p53 complexes in PML nuclear bodies). The mechanisms by which FOXO4-DRI achieves intracellular access have not been fully characterized. Cell-penetrating properties may be facilitated by the peptide's sequence characteristics, but the efficiency of delivery across different tissue types remains poorly defined.

Incomplete Molecular Characterization#

Several aspects of the molecular characterization of FOXO4-DRI remain incomplete in the published literature. The full molecular formula has not been reported. No CAS number has been assigned. The exact amino acid sequence, while based on the FOXO4-p53 binding domain, has been reported with some variation in secondary and commercial sources. No crystal structure or NMR structure of FOXO4-DRI bound to p53 has been published. The tissue distribution, cellular uptake efficiency, and intracellular localization kinetics of FOXO4-DRI following systemic administration have not been quantitatively defined.

These gaps complicate efforts to standardize research-grade material and to compare results across studies or commercial preparations that may use different peptide syntheses.

Stability and Storage#

Specific stability data for FOXO4-DRI under various storage conditions have not been reported in the peer-reviewed literature. Based on general peptide chemistry principles and the properties of D-amino acid peptides, FOXO4-DRI is expected to demonstrate greater stability than equivalent L-amino acid peptides under physiological conditions due to its resistance to proteolytic degradation. Standard peptide storage practices (lyophilized powder stored at -20 degrees Celsius or below, reconstituted solutions stored at 2-8 degrees Celsius and used within a defined period, protection from light and repeated freeze-thaw cycles) would apply in the absence of compound-specific stability data.

Related Reading#

• FOXO4-DRI overview and research guide
• Peptides similar to FOXO4-DRI
• FOXO4-DRI research evidence